NLM Logo

Clinical Trials, Phase IV as Topic MeSH Descriptor Data 2023


MeSH Heading
Clinical Trials, Phase IV as Topic
Tree Number(s)
E05.318.372.250.250.230
E05.337.800.200
N05.715.360.330.250.250.230
N06.850.520.450.250.250.230
Unique ID
D017327
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D017327
Annotation
for general design, methodology, economics, etc. of phase IV clinical trials; a different heading CLINICAL TRIAL, PHASE IV is used for reports of a specific phase IV clinical trial
Scope Note
Works about planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.
Entry Term(s)
Clinical Trials, Phase 4 as Topic
Drug Evaluation, FDA Phase 4 as Topic
Drug Evaluation, FDA Phase IV as Topic
Evaluation Studies, FDA Phase 4 as Topic
Evaluation Studies, FDA Phase IV as Topic
Previous Indexing
Clinical Trials (1980-1992)
See Also
Drug-Related Side Effects and Adverse Reactions
Public MeSH Note
2008; see CLINICAL TRIALS, PHASE IV 1993-2007; for DRUG EVALUATION, FDA PHASE IV see CLINICAL TRIALS 1981-1992; for EVALUATION STUDIES, FDA PHASE IV see CLINICAL TRIALS 1982-1992
History Note
2008(1993)
Date Established
1993/01/01
Date of Entry
1992/05/13
Revision Date
2019/07/05
Clinical Trials, Phase IV as Topic Preferred
Drug Evaluation, FDA Phase IV as Topic Related
page delivered in 0.167s